COMPOSITIONS FOR USE IN CARDIOPLEGIA COMPRISING ESMOLOL AND ADENOSINE
The invention related to a composition for use in cardioplegia, said composition comprising (i) esmolol; and (ii) adenosine, wherein in use the concentration of said esmolol is in the range 0.3-1.5 mM, and wherein in use the concentration of said adenosine is in the range 0.1-1.5 mM. The invention also relates to methods of making and using such compositions.
1 . A composition for use in cardioplegia, said composition comprising
(i) esmolol; and
(ii) adenosine,
wherein in use the concentration of said esmolol is in the range 0.3-1.5 mM, and
wherein in use the concentration of said adenosine is in the range 0.1-1.5 mM.
2 . A composition according to claim 1 wherein the concentrations of esmolol and adenosine correspond to a single point in the enclosed area on the graph of FIG. 4 .
3 . A composition according to claim 2 wherein the concentrations of esmolol and adenosine correspond to a single point in the hatched area on the graph of FIG. 4 .
4 . A composition according to claim 1 , wherein the product of the concentration of esmolol and of adenosine is at least 0.15.
5 . A composition according to claim 4 wherein the product of the concentration of esmolol and of adenosine is at least 0.3.
6 . A composition according to claim 1 , wherein said composition comprises a blood preparation.
7 . A composition according to claim 1 , wherein said composition comprises a crystalloid preparation.
8 . A composition according to claim 1 wherein said composition comprises 0.6 mM esmolol and 0.25 mM adenosine.
9 . A composition according to claim 1 , wherein said esmolol and adenosine are dissolved in a solvent consisting essentially of Ringer solution.
10 . A composition according to claim 1 , further comprising 10 mM Mg 2+ .
11 . A method of inducing cardioplegia comprising administering to a subject a composition according to claim 1 .
12 .- 14 . (canceled)
15 . An ampoule comprising
(i) 25 mM adenosine
(ii) 60 mM esmolol
in aqueous solution.
17 .- 19 . (canceled)
20 . The method according to claim 11 wherein said composition is administered at 22-24 degrees Celsius.
21 . A composition for use in manufacture of a cardioplegic solution, said composition comprising a stock solution of esmolol and adenosine, wherein upon dilution of said stock solution for use in a subject the stock solution can be diluted to a concentration of said esmolol in the range 0.3-1.5 mM and the concentration of said adenosine in the range 0.1-1.5 mM.
22 . The composition of claim 21 , wherein said stock solution comprises esmolol in the concentration range 0.6-150 mM and adenosine in the concentration range 0.2-150 mM.